Article
Characteristics and Predictive Value of PD-L1 Status in Real-World Non-Small Cell Lung Cancer Patients.
Journal of immunotherapy (Hagerstown, Md. : 1997) - 1 Jan 2000
Tseng Jeng-Sen, Yang Tsung-Ying, Wu Chih-Ying, Ku Wen-Hui, Chen Kun-Chieh, Hsu Kuo-Hsuan, Huang Yen-Hsiang, Su Kang-Yi, Yu Sung-Liang, Chang Gee-Chen
Abstract excerpt
Immunotherapy targeting the programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) pathway has emerged as an effective treatment for lung cancer patients. It is important to evaluate the practicality of PD-L1 testing in real-world practice. A total of 211 non-small cell lung cancer patients were enrolled to detect 5 driver mutations and PD-L1 status (22C3 and SP263 assays) and to evaluate the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
